Welcome to Markets Desk, here's what's moving the tape this Monday.
Rocket Lab shares closed Friday at sixty-three dollars and ninety-one cents, roughly fifty-eight percent below their peak of one hundred fifty-one dollars. Wall Street's average price target sits nearly seventy-nine percent above current levels, meaning either analysts are dramatically wrong or the market is leaving serious value on the table — and that gap demands attention.
Shifting to corporate restructuring, Boston Scientific has filed an eight-K with the SEC outlining a sweeping global reorganization. The board-approved plan targets operational streamlining and supply chain optimization, with workforce reductions expected as part of the effort. Investors will be watching closely for guidance on the scope and timeline of those cuts.
And over in Paris, Renault is headed to criminal court on aggravated fraud charges, accused of equipping older diesel vehicles with devices designed to circumvent emissions regulations. The case echoes the Volkswagen scandal that rocked the auto sector years ago, and a conviction could carry significant financial and reputational consequences for the French automaker.
That's the tape. Markets Desk, signing off the floor.
